The carnage of substandard research during the COVID-19 pandemic: a call for quality

Katrina A Bramstedt 1,2

ABSTRACT
Worldwide, there are currently over 1200 research studies being performed on the topic of COVID-19. Many of these involve children and adults over age 65 years. There are also numerous studies testing investigational vaccines on healthy volunteers. No research team is exempt from the pressures and speed at which COVID-19 research is occurring. This can increase the risk of honest error as well as misconduct. To date, 33 papers have been identified as unsuitable for public use and either retracted, withdrawn, or noted with concern. Asia is the source of most of these manuscripts (n=19; 57.6%) with China the largest Asian subgroup (n=11; 57.9%). This paper explores these findings and offers guidance for responsible research practice during pandemics.

INTRODUCTION
As of 7 May 2020, the international clinical trial registry site, ClinicalTrials.gov, reported 1221 registered studies focused on COVID-19 (table 1). 1 Of these, 214 (17.5%) include children as research participants, and 1155 (94.6%) include adults age 65 years and older. Healthy volunteers are the cohort for 243 (19.9%) studies, and of these, 13 (5.4%) are vaccine clinical trials. Most studies are being performed in Europe and North America where research ethics regulations are robust; however, no location is exempt from the pressures and speed at which COVID-19 research is occurring. This can increase the risk of honest error as well as misconduct. 1

According to WHO, the first cases of COVID-19 occurred in China in December 2019. 2 Other sources indicate the first case could have been in November 2019. 3 As the virus rapidly spread from an epidemic to a pandemic, researchers worldwide began the search for treatments and vaccines. Journals have been flooded with manuscript submissions 4 and more journals are providing open access, 5 allowing the research to be readily viewed by clinicians who can potentially then use the research for clinical decision-making.

PROBLEMATIC PANDEMIC RESEARCH PUBLICATIONS
As of 31 July 2020, 19 published articles and 14 preprints about COVID-19 have been retracted, withdrawn, or an expression of concern has been issued (tables 2 and 3). 6 The source of most of these incidents is Asia (n=19; 57.6%), with China the largest Asian subgroup (n=11; 57.9%). For three papers, the reason for the removal is unknown; however, for the others, a range of problems exist, including data falsification, methodological concerns, and concerns about interpretation of data and conclusions, as well as authorship and research participant privacy issues (table 4). To date, there have been no identified reports of plagiarism or data fabrication. Another paper, a preprint from the USA about COVID-19 antibody seroprevalence, has come under scrutiny for an undisclosed conflict of interest, but no official findings have been issued. 6,7

COMPLICATIONS OF PUBLISHING PROBLEMATIC RESEARCH
There has been a surge of almost 4000 papers related to COVID-19 placed on preprint servers recently. 8 These platforms provide a lower level of quality checks compared with a full peer review process by journals. Accordingly, preprint platforms do routinely advise their readers not to use their content for clinical decision-making, but the latter cannot be ruled out, especially in the situation of a pandemic with high rates of morbidity and mortality. Patient harm that is significant, permanent and irreversible could result from using faulty research results from preprints as well as published papers. Published papers are interpreted as vetted via peer review, with an inference of quality and accuracy and clinicians are likely to refer to them for guidance.

The act of retraction follows a thorough investigation and concern about a paper’s integrity (eg, methods, data analysis, data interpretation, data reporting). While not as severe as a retraction, an expression of concern announces to potential readers that a paper should be read with caution due to potential integrity issues. Both retraction and expression of concern are markers of integrity issues that reflect on the authors and their institutional affiliation. Retracted research can have direct funding costs due to waste and payback requirements, as well as decreased future funding. 9 Sometimes, the integrity of the journal can also be implicated if the matter is associated with a less

1 Luxembourg Agency for Research Integrity, Esch-sur-Alzette, Luxembourg
2 Bond University Faculty of Health Sciences and Medicine, Gold Coast, Queensland, Australia

Correspondence to Professor Katrina A Bramstedt, Bond University Faculty of Health Sciences and Medicine, Gold Coast, Queensland, Australia; txbioethics@yahoo.com

Received 23 May 2020
Revised 1 August 2020
Accepted 12 August 2020
Published Online First 1 October 2020


7Retraction Watch (https://retractionwatch.com/retracted-coronavirus-covid-19-papers) was used as the source of these articles as they catalogue articles from numerous journal indexing databases beyond MEDLINE, as well as preprint servers. The source also mentioned one COVID-19-related conference paper that was withdrawn before presentation with unclear explanation.
can potentially be harmed by a colleague’s misconduct. Research has shown that in such situations, the citations of prior collaborators can fall by 8–9%.10 There can be additional harm to personal relationships amid and across teams as well, and unhappiness can negatively impact productivity.11

**PREVENTING SUBSTANDARD RESEARCH**

Research normally occurs at the speed of a marathon, but during a pandemic, the pace is more like a sprint.1 The prior slower pace gave space for reflection on quality, as well as time for researchers to rest their minds and bodies. During the pandemic there is the potential for the race of research to occur with fewer reflective and rest periods. Less reflection can facilitate missed opportunities for quality checks such as robust reviews of study applications by research ethics committees (RECs) and quality checks by researchers and their supervisors. Less rest can facilitate fatigue and mistakes of human error or judgement (eg, taking short cuts rather than performing standard practice).12 During a pandemic, research teams should build in time for reflection such as scheduled spot-checking of data.13 Rejuvenation time can also be scheduled such as a team exercise break for a brisk walk around the campus (respecting social distancing) or even a fun musical tune blasted across the public announcement system signalling a 3 min brain break.

RECs cannot be expected to routinely have membership of immunologists, microbiologists and pulmonologists, for example, yet these are key topic experts for research protocols dealing with COVID-19. In an effort to provide high-quality reviews of these protocols, RECs should create a list of go-to experts who can be retained as consultants for these reviews. These experts can be readily found through a search of PubMed or international scientific professional societies. Some universities also provide experts collated by topic on their websites. It is not enough to have a fast-track review process that speeds the protocol submissions through the REC; a robust review process that reflects on both science and ethics is needed. Considering that many COVID-19 projects involve epidemiology and contact tracing, reviewers should also pay special attention to the privacy protection of human participants.

Research ethics and integrity training should be mandatory for all researchers so that they have a foundational understanding of

### Table 2 Problematic COVID-19 preprint articles

<table>
<thead>
<tr>
<th>Source</th>
<th>Issue</th>
<th>Location of corresponding author’s institution</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRN10</td>
<td>Dataset is linked to two other retracted papers11,12</td>
<td>USA</td>
<td>Retracted</td>
</tr>
<tr>
<td>SSRN10</td>
<td>Dataset is linked to two other retracted papers11,12</td>
<td>USA</td>
<td>Retracted</td>
</tr>
<tr>
<td>SSRN10,16</td>
<td>Numerous concerns including authorship, statistical analysis, findings</td>
<td>Indonesia</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>bioRxiv13</td>
<td>Article lacked the full consent for publication by all authors</td>
<td>China</td>
<td>Retracted</td>
</tr>
<tr>
<td>bioRxiv13</td>
<td>Authors’ desire to perform additional research to validate their work</td>
<td>China</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Authors’ desire to update their dataset to enlarge it</td>
<td>China</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Authors’ desire to perform additional research to validate their work</td>
<td>China</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>bioRxiv13</td>
<td>Consent was not obtained for use of the study dataset</td>
<td>Bangladesh</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Controversy about hydroxychloroquine and a retrospective study design</td>
<td>France</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>bioRxiv14</td>
<td>Concerns regarding technical approach and data interpretation</td>
<td>India</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Study performed beyond scope of the research ethics committee approval</td>
<td>Italy</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Study performed beyond scope of the research ethics committee approval</td>
<td>Italy</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Controversy about hydroxychloroquine; results potentially different after peer review.</td>
<td>South Korea</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>medRxiv</td>
<td>Privacy concerns regarding research participants</td>
<td>USA</td>
<td>Withdrawn</td>
</tr>
</tbody>
</table>
Research courses that embrace both ethics and quality, and they can potentially deter misconduct and substandard practice, as well as the consequences of both good research practice, ethical sensitivities, types of research. These courses are offered online. Researchers should have ready access to services which can provide timely, expert advice to research dilemmas involving topics such as authorship disputes, image manipulation, citations and referencing, informed consent, participant recruitment, and so on. These services could include an online FAQ, an ethics consult service or video tutorials. Another option is on-site research coaches who are an adjunct to the research supervisor, available for quick advice. ‘Publish or perish’ is a harmful mindset and the pandemic’s ‘need for speed’ needs calibration which can be aided by coaching, supervision and mentoring that recognises the humanness of the research process. Researchers need advice, support, rest and tools.

Robust peer review of manuscripts is vital, especially when open access publishing makes them easy to find and view in full text. The pandemic has created a surge of manuscripts, yet the fleet of journal peer reviewers is a voluntary service to the research community in the setting of concurrent commitments which often include employment and family. The research topics are often complex and highly specialised and thus the peer review assignment must be thoughtful, and include avoiding conflict of interest (eg, research competitor, sponsor funding). Journals must also mitigate time when manuscripts age with long peer review times when reviewers cannot be secured. Rapid review should not compromise the quality of the review, but rather the efficiency of the process should be improved by identifying bottlenecks, removing steps that do not add value, and

Table 3  Problematic COVID-19 published articles

<table>
<thead>
<tr>
<th>Journal</th>
<th>Indexing</th>
<th>Issue</th>
<th>Location of corresponding author's institution</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Journal of Antimicrobial Agents</td>
<td>MEDLINE</td>
<td>Concern regarding method, ethics review, and peer review</td>
<td>France</td>
<td>Expression of concern</td>
</tr>
<tr>
<td>Lancet Global Health</td>
<td>MEDLINE</td>
<td>Data falsification</td>
<td>China</td>
<td>Retracted</td>
</tr>
<tr>
<td>Zhonghua Er Ke Za Zhi Chinese Journal of Pediatrics</td>
<td>MEDLINE</td>
<td>Unknown</td>
<td>China</td>
<td>Retracted</td>
</tr>
<tr>
<td>Cellular &amp; Molecular Immunology</td>
<td>MEDLINE</td>
<td>Invalid conclusions due flawed test methodology and incorrect biological material for study</td>
<td>USA</td>
<td>Retracted</td>
</tr>
<tr>
<td>Lancet</td>
<td>MEDLINE</td>
<td>Authors unable to arrange an independent audit of the data foundational to the study due to blocked data access</td>
<td>USA</td>
<td>Retracted</td>
</tr>
<tr>
<td>New England Journal of Medicine</td>
<td>MEDLINE</td>
<td>Authors unable to arrange an independent audit of the data foundational to the study due to blocked data access</td>
<td>USA</td>
<td>Retracted</td>
</tr>
<tr>
<td>Bulletin de la Dialyse à Domicile</td>
<td>DOAJ</td>
<td>Data erroneous</td>
<td>France</td>
<td>Retracted</td>
</tr>
<tr>
<td>Lancet</td>
<td>MEDLINE</td>
<td>Article is a commentary on a paper that subsequently was retracted</td>
<td>France</td>
<td>Retracted</td>
</tr>
<tr>
<td>Journal of Molecular Pharmaceuticals and Regulatory Affairs</td>
<td>DRJI</td>
<td>The information pertaining in this paper is misleading the readers and creating massive conflicts amid the scientific community</td>
<td>India</td>
<td>Retracted</td>
</tr>
<tr>
<td>Journal of Biological Regulators &amp; Homeostatic Agents</td>
<td>MEDLINE</td>
<td>Corrupted peer review process</td>
<td>Italy</td>
<td>Retracted</td>
</tr>
<tr>
<td>Annals of Internal Medicine</td>
<td>MEDLINE</td>
<td>Findings below the limit of detection thus unreliable</td>
<td>South Korea</td>
<td>Retracted</td>
</tr>
<tr>
<td>Chinese Journal of Epidemiology</td>
<td>MEDLINE</td>
<td>Concern regarding results and conclusions</td>
<td>China</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Practical Preventive Medicine</td>
<td>China Academic Literature Database</td>
<td>Concern regarding method, ethics review, and peer review</td>
<td>China</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Journal of the American Pharmacists Association</td>
<td>MEDLINE</td>
<td>Publisher’s accidental duplication of another publication in the same journal</td>
<td>USA</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Journal of the American Pharmacists Association</td>
<td>MEDLINE</td>
<td>Publisher’s accidental duplication of another publication in the same journal</td>
<td>USA</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Travel Medicine and Infectious Disease</td>
<td>MEDLINE</td>
<td>Another research team submitted the same case report to another journal</td>
<td>Iran</td>
<td>Withdrawn</td>
</tr>
<tr>
<td>Engineering</td>
<td>DOAJ; Scopus</td>
<td>Language editing required to improve paper’s clarity</td>
<td>China</td>
<td>Temporarily retracted but returned online</td>
</tr>
<tr>
<td>Journal of the American Academy of Dermatology</td>
<td>MEDLINE</td>
<td>Unknown</td>
<td>China</td>
<td>Temporarily retracted but returned online</td>
</tr>
<tr>
<td>American Journal of Obstetrics and Gynaecology</td>
<td>MEDLINE</td>
<td>Journal production error in title of manuscript (delete word ‘effective’)</td>
<td>Turkey</td>
<td>Temporarily removed from journal but returned after correction</td>
</tr>
</tbody>
</table>

*DRJI (Directory of Research Journal Indexing) is noted to be a ‘misleading metric’ index per https://predatoryjournals.com/metrics/#D. DOAJ, Directory of Open Access Journals.
Table 4 Research ethics and integrity concerns

<table>
<thead>
<tr>
<th>Issue</th>
<th>No of papers*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methodology (eg, wrong method; wrong specimen; need more experiments; study design)</td>
<td>8</td>
</tr>
<tr>
<td>Consent (ie, study participants; data sharing partners)</td>
<td>6</td>
</tr>
<tr>
<td>Deception (eg, data interpretation)</td>
<td>6</td>
</tr>
<tr>
<td>Other (eg, sensitive topic; peer review feedback)</td>
<td>4</td>
</tr>
<tr>
<td>Research Ethics Committee</td>
<td>3</td>
</tr>
<tr>
<td>Unknown</td>
<td>3</td>
</tr>
<tr>
<td>Authorship</td>
<td>2</td>
</tr>
<tr>
<td>Peer review</td>
<td>2</td>
</tr>
<tr>
<td>Falsification</td>
<td>1</td>
</tr>
<tr>
<td>Duplicate manuscript submission</td>
<td>1</td>
</tr>
<tr>
<td>Privacy</td>
<td>1</td>
</tr>
<tr>
<td>Statistics</td>
<td>1</td>
</tr>
</tbody>
</table>

*Preprints and published papers; some papers evidenced multiple concerns.

incorporating staff and tools for the administrative/document handling tasks.18 19

When research integrity problems are found, they should be documented in a professional manner that includes whistle-blower protection. Confirmed infractions of policies and standards should have meaningful consequences that reflect on root cause in order to deter repeat offences. Also, by publishing the results of investigations, these can be used for training purposes, and routine trending for areas of organisational concern can be identified (eg, supervision issues).

It is also important to announce when investigations do not confirm misconduct or research quality issues so that accused personnel can be vindicated. There may be regional regulations that restrict the personal details of publishing integrity investigations (eg, European Union General Data Protection Regulation); however, there is value in publishing of anonymised case summaries for both institutional transparency and training purposes. National research integrity offices can be sources of investigation summaries, training and consultation for researchers of all levels, and their continued support and funding is vital to fostering ethical and robust research.

Twitter Katrina A Bramstedt @AskTheEthicist

Contributors Bramstedt KA is the sole author.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests The author owns a private consulting company focused on bioethics and clinical ethics (AskTheEthicist, LLC).

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon request.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, personal or commercial purposes, provided that the source is clearly identified as this article and not modified or interpreted in any way.

Acknowledgements This study... 

Funding

This work was supported by a grant from the Social Science and Humanities Research Council of Canada (SSHRC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics approval

This study was approved by the institutional ethics review board at the University of British Columbia (H19-02699).

Consent for publication

Written consent was obtained from all participants.

Competing interests

None.

Patient consent for publication

Not required.

Data availability statement

The dataset for this study is available upon request from the corresponding author.

ORCID ID

Katrina A Bramstedt http://orcid.org/0000-0001-5446-0123

REFERENCES


19 Peyrin-Biroulet L. Will the quality of research remain the same during the COVID-19 pandemic? Clin Gastroenterol Hepatol 2020;18(9).

20 ALLEA All European Academies. The European code of conduct for research integrity. Berlin, Germany: ALLEA – All European Academies, 2017.


COVID-19 pandemic has created flood of potentially substandard research

- Rush to publish is testing research integrity process
- 33 papers retracted, withdrawn, or had serious doubts raised as of end of July
- Thousands of COVID papers on pre-print servers where fewer quality checks made

The COVID-19 pandemic has created a flood of potentially substandard research amid the rush to publish, with a string of papers retracted or under a cloud and a surge in submissions to pre-print servers where fewer quality checks are made, a leading ethicist has warned in the *Journal of Medical Ethics*.

This has implications for patients, clinicians, and potentially government policy, says Adjunct Professor Katrina Bramstedt, Bond University, Queensland, Australia and Secretary General at Luxembourg Agency for Research Integrity.

The rapid spread of COVID-19 and its transition into a global pandemic propelled researchers to begin the search for treatments and vaccines in earnest.

Scientific and medical Journals have since been flooded with submissions, while thousands of papers, which have not undergone thorough quality checks, have been posted on preprint servers.

As of 7 May 2020, 1221 studies on COVID-19 were registered on the international clinical trial registry site, ClinicalTrials.gov.

And as of 31 July 2020, 19 published articles and 14 preprints about COVID-19 have been retracted, withdrawn, or had serious doubts raised about the integrity of their data, formally known as an expression of concern.

Most of these papers came from Asia (n=19; 57.5%), with over half coming from China (n=11; 58%).

But as the author points out: “No research team is exempt from the pressures and speed at which COVID-19 research is occurring. And this can increase the risk of honest error as well as deliberate misconduct.”

The reason for the removal of the 33 papers isn’t known in 3 cases, but data falsification, methodological issues, and concerns about interpretation of data and conclusions, as well as authorship and participant privacy issues were among the reasons in the other papers.

Two preprints (SSRN preprint server) and two research papers in *The Lancet* and *New England Journal of Medicine* were retracted because of unverifiable data common to all four.
And a preprint from the USA about COVID-19 antibody seroprevalence has come under scrutiny for an undisclosed conflict of interest.

There are obvious implications for the journal and the researchers involved, even if they are innocent of any research misconduct, points out the author. The evidence suggests that in such cases, the citations of prior collaborators can take a hit and fall by 8–9%.

But there are also implications for patients. “Patient harm that is significant, permanent and irreversible could result from using faulty research results from preprints as well as published papers,” she says.

The rush to publish means there is less time for quality checks by researchers and their supervisors and for thorough reviews of study applications by research ethics committees, says Professor Bramstedt.

Added to which, these committees can’t be expected to routinely include the key experts needed for COVID-19 research, such as immunologists, microbiologists and lung disease specialists.

Journals, too, rely on a fleet of peer reviewers, all of whom work on a voluntary basis and have competing demands on their time.

To counter these issues, the author suggests that the efficiency of the submission process is tightened up and that research ethics and integrity training be mandated for all researchers.

They should also have timely access to ethical advice on research dilemmas involving topics such as authorship disputes, image manipulation, citations and referencing, informed consent, ethical participant recruitment, etc.

Any infractions of policies and standards should have meaningful consequences to ward off repeat offences, she suggests, adding that it’s important to publicise the results of any investigations, whatever the outcome.

In a personal comment, not found in the text, Professor Bramstedt emphasizes: "Research has the potential to enter the public domain and be used by many stakeholders, including governments and policy makers, so the data must be robust."

**Journal of Medical Ethics** editor, Professor John McMillan, adds: "Researchers face powerful headwinds against their efforts to further knowledge about COVID-19. The urgency for evidence, the rewards from finding a successful therapy or vaccine, and the prevalence of disinformation mean scientific integrity is critically important.

"Professor Bramstedt's report is an early warning for journals and preprint servers to be proactive and maintain rigour when assessing research."